Affiliations 

  • 1 Department of Pharmacology, Pannai College of Pharmacy, Dindigul, Tamil Nadu, 624005, India. pbala2006@gmail.com
  • 2 Shoppers Drug Mart, Waterloo, ON, N2T2Z7, Canada
  • 3 Department of Pharmacology, College of Pharmacy, King Khalid University, Guraiger, 62529, Abha, Kingdom of Saudi Arabia
  • 4 Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Guraiger, 62529, Abha, Kingdom of Saudi Arabia
  • 5 Department of Pharmacology, Pannai College of Pharmacy, Dindigul, Tamil Nadu, 624005, India
  • 6 Faculty of Pharmacy, AIMST University, Semeling, 08100, Bedong, Malaysia
  • 7 College of Pharmacy, California Health Sciences University, Clovis, CA, 93612, USA
Cardiovasc Toxicol, 2022 Feb 10.
PMID: 35143015 DOI: 10.1007/s12012-022-09724-y

Abstract

Among numerous choices in cardiovascular therapies used for the management of hypertension and heart failure, drugs affecting the renin-angiotensin-aldosterone system (RAAS) hold substantial therapeutic roles. Therapies aimed at modifying the RAAS and its overactivation are employed for the management of various insidious disorders. In the pharmacologic perspective, RAAS is one of the frequently manipulated systems for the management of hypertension, heart failure, myocardial infarction, and renal disease. The RAAS pharmacologic interventions principally include the ACE inhibitors, the angiotensin II-AT1 receptor blockers, the mineralocorticoid receptor antagonists, and the direct renin inhibitors. In addition, therapeutic implication of ACE2/angiotensin (1-7)/Mas receptor activation using various ligands is being explored owing to their anti-inflammatory, anti-fibrotic, vasodilatory, and cardiovascular defensive roles. Moreover, being considered as the counter-regulatory arm of AT1 receptor, the potential role of AT2 receptor activation using selective AT2 receptor agonist is currently investigated for its efficacy in pulmonary complications. As an important regulator of fluid volume, blood pressure, and cardiovascular-renal function, the RAAS has been documented as a diversified intricate system with several therapeutic possibilities coupled with their fundamental structural and functional modulatory roles in cardiovascular, renal, and other systems. The RAAS possesses a number of regulatory, deregulatory, and counter-regulatory axes of physiopathologic importance in health and disease. The counter-regulatory arms of the RAAS might play an essential role in mitigating cardiovascular, renal, and pulmonary pathologies. In light of this background, we sought to explore the classical and counter-regulatory axes/arms of the RAAS and their imperative roles in physiologic functions and disease pathogenesis.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.